SLC5A2 and Stroke: As diabetes and hypertension coexist, the use of empagliflozin (perhaps other SGLT2 inhibitors) in this high-risk diabetic population may complement conventional antihypertensive therapy to potentially reduce the overall risk of adverse cardiovascular events such as heart attack and stroke.